ECUATORIAN JOURNAL OF PEDIATRICS PROTOCOLS rev-sepp.ec * Corresponding autor: Email: torres.maritza88@gmail.com (Maritza Torres Valdez). Manuel Arturo Cisneros y Av. De las Américas Azuay-Cuenca, Ecuador., Postal code: 010206, Phone: [593]098 6511936. Revista Ecuatoriana de Pediatría. 2021: Article 2 pages 1-8 Received: November 1, 2020 Accepted: February 2, 2021 Published: April 30, 2021 Editor: Dr. Paúl Astudillo Neira . Bibliographic letterhead: Torres M, Muñoz L, Ortega C, Mora F, Barzallo D. Reduction of cardiovascular events with Lo- mitapida versus Statins in pa- tients with a diagnosis of familial hypercholesterolemia: A system- atic review protocol. Rev. Ecuat. Pediatria 2021: 22 (1): Article 1: 1-8. Doi: 10.52011 / 0097 Copyright Torres M, et al. This article is distributed under the terms of the Creative Commons Attribution License CC BY-NC-SA 4.0 , which allows its use and re- distribution citing the source and original author for non-commer- cial purposes. DOI: https:/ / doi.org/ 10.52011/ 0097 Reduction of cardiovascular events of Lomitapida versus Statins in patients with a diagnosis of familial hypercholesterolemia: A systematic review protocol. Maritza Torres Valdez 1 * , Lorena Alexandra Muñoz Avila 2 , Carlos Enrique Ortega Espinoza 3 , Franklin Geovany Mora Bravo 2 , Diego Fernando Barzallo Zeas 4 1. Baños Health Center, Ministry of Public Health, Cuenca, Ecuador. 2. School of Medicine, Faculty of Medical Sciences, Universidad de Cuenca, Ecuador. 3. Internal Medicine Service, General Hospital of Ibarra, Ecuadorian Institute of Social Security, Ibarra l, Ibarra, Ecuador. 4. School of Medicine, Faculty of Medical Sciences, Universidad del Azuay, Ecuador Abstract Introduction: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that produces hypercholesterolemia and premature development of cardiovascular dis- eases. Statins are the drug of choice in these patients; however, a high percentage of patients cannot achieve their therapeutic goals with the maximum recommended doses, so Lo- mitapide may prove to be useful as a new treatment alternative to traditional statins. Objective: The objective of this systematic review is to determine if Lomitapide is better than statins at reducing cardiovascular events in patients with a diagnosis of FH. M ethods: Randomized controlled trials (RCTs) and quasi-randomized trials of patients diag- nosed with FH will be included. Primary outcome measures included several parameters: 1. Post-treatment low- and high-density lipoprotein (LDL and HDL, respectively) levels and 2. Presence of cardiovascular events. Electronic searches will be conducted in PUBMED, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, and the scientific elec- tronic library (Scielo). The assessment of the risk of bias will be used by the Cochrane tool. The measures of the treatment effect will be considered the mean differences (MD) and the 95%confidence intervals (CI). The evaluation of heterogeneity will be done by visual inspec- tion of the funnel diagram. The evaluation of the quality of the evidence will be done using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) ap- proach. Keywords: Lipoproteins, LDL; Hydroxymethylglutaryl CoA Reductases; Cardiovascular Dis- eases; Anticholesteremic Agents; Hypercholesterolemia; Cholesterol, LDL; Systematic Review; Protocols. PROSPERO database record number (York University): CRD42020213807